- Xedev has expanded its GMP authorization to include the manufacturing and primary packaging of liquids for internal use.
- The company, already approved for non-sterile and biological medicinal products, now supports liquid formulation projects alongside its existing services in solid drug product development and manufacturing.
Xedev has successfully extended its Good Manufacturing Practice (GMP) authorization to cover the manufacturing and primary packaging of liquid formulations intended for internal use. The expansion broadens the company’s existing approval, which already includes non-sterile and biological medicinal products.
With this authorization, Xedev now offers support for projects involving liquid formulations alongside its core expertise in formulation and process development for solid drug products. The company provides tailored solutions to meet customer requirements, ensuring efficient product development and manufacturing.
Xedev’s capabilities include manufacturing for research and development (R&D) and GMP batches, supporting pharmacokinetic (PK), toxicology (Tox), and early-phase clinical studies. The company offers flexible production options, catering to both small-scale and large-scale batch sizes.
